Beretta Holding, the largest shareholder of Sturm, Ruger & Company, Inc., sent a letter to Ruger’s board on March 25 2026 proposing an all‑cash, premium partial tender offer for up to 20.05% of the company’s outstanding shares. The offer price of $44.80 per share represents a roughly 20% premium to the 60‑day average price and a 10% premium to the closing price on March 24, 2026.
The proposal includes a request for an exemption from Ruger’s shareholder rights plan, which would allow Beretta to acquire up to 30% beneficial ownership. Ruger’s board members collectively own less than 1% of the company, while Beretta currently holds about 9.95% of the shares. Ruger adopted its poison‑pill defense on October 14 2025, and the tender offer is contingent on the board granting the exemption by March 31 2026.
Beretta’s stated intent is to deepen its partnership with Ruger rather than to gain control. The company has previously nominated four directors to Ruger’s board in February and has indicated a long‑term plan to combine the two companies. Management has emphasized that a 30% stake would not confer veto power or control, but would enable a closer strategic collaboration to improve Ruger’s operational and financial performance.
Ruger’s recent financial results provide context for the offer. In Q4 2025, the company reported earnings per share of $0.26, falling short of the $0.41 consensus estimate, while revenue of $151.1 million exceeded the $139.94 million forecast. The company’s market capitalization is approximately $649.57 million, and it has faced declining profitability margins and challenges in revenue growth, prompting Beretta’s interest in a partnership that could address these headwinds.
Following the announcement, Ruger shares rose 5.2% in pre‑market trading, reflecting investor appetite for the premium tender offer and the potential for a strategic partnership. The market reaction underscores the attractiveness of the offer price and the perceived value of a partnership that could enhance Ruger’s competitiveness.
The tender offer will proceed only if Ruger’s board grants the poison‑pill exemption by March 31 2026. If approved, Beretta could increase its stake to 30% and potentially influence board composition and strategic decisions, while Ruger shareholders would have the option to sell at a premium. The outcome will shape the company’s ownership structure and governance dynamics moving forward.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.